• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789

Introduction to 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1190313-99-5)

5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1190313-99-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrrolopyridines, which are known for their diverse biological activities and potential therapeutic applications. The unique combination of bromine, iodine, and methyl groups in its structure makes it a valuable scaffold for the development of novel drugs targeting various diseases.

The structural features of 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine contribute to its high reactivity and versatility in chemical synthesis. The bromine and iodine substituents provide excellent leaving groups for various substitution reactions, making it an ideal starting material for the synthesis of more complex molecules. Additionally, the presence of the methyl group enhances the lipophilicity of the compound, which can be crucial for improving its bioavailability and cellular uptake.

Recent studies have highlighted the potential of 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine in the development of anticancer agents. Research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent antiproliferative activity against various cancer cell lines. Specifically, these derivatives have been found to inhibit key signaling pathways involved in cell proliferation and survival, such as the PI3K/AKT and MAPK pathways.

In addition to its anticancer properties, 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine has also shown promise in the treatment of neurodegenerative diseases. Studies conducted at leading research institutions have demonstrated that certain derivatives of this compound can effectively modulate neurotransmitter systems and protect neurons from oxidative stress and inflammation. These findings suggest that 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine could serve as a lead compound for the development of novel neuroprotective agents.

The synthetic accessibility of 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine has been a key factor in its widespread use in drug discovery programs. Several efficient synthetic routes have been developed to prepare this compound on a large scale, making it readily available for further optimization and functionalization. One such route involves a palladium-catalyzed cross-coupling reaction between a bromopyrrole derivative and an iodopyridine precursor, followed by methylation to introduce the methyl group.

The physicochemical properties of 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine, including its solubility, stability, and logP value, have been extensively characterized. These properties are crucial for optimizing its formulation and delivery methods in pharmaceutical applications. For instance, the compound's moderate solubility in organic solvents and its stability under physiological conditions make it suitable for use in both oral and parenteral formulations.

In conclusion, 5-Bromo-3-iodo-4-methyl-1H-pyrrolo[2,3-b]pyridine (CAS No. 1190313-99-5) is a highly promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features, synthetic accessibility, and favorable physicochemical properties make it an attractive scaffold for the development of novel therapeutic agents targeting cancer and neurodegenerative diseases. Ongoing research continues to uncover new derivatives and analogs with enhanced biological activities, further solidifying its importance in the field.

• 757978-18-0(5-Bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine)
• 1092579-77-5(Butanoic acid, 2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)